Drug Trial Radar · NCT02391727
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
May 2015
Primary completion
Oct 2018
Study completion Oct 2018
Sponsor
- Lead sponsor
- Synermore Biologics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human evaluation of SYN004, a monoclonal antibody that binds to the EGF receptor on cancer cells. Cetuximab, a marketed antibody, has been shown to be effective by inhibiting the growth of cancer cells thereby prolonging the life of patients who have received it. SYN004 is a closely related monoclonal antibody also binds to the EGF receptor in the same way. SYN004 might also inhibit cancer cells and prolong life but has been engineered to avoid some of the hypersensitivity reactions known to provoked by cetuximab.
Conditions
- Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Interventions
SYN004Biological
subjects who have received effective treatment for their cancers are eligible
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse eventsTime frame: 28 days of last SYN004 Administration
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Ochsner Medical Center
New Orleans, Louisiana
Washington University Medical Center
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.